PD with pain n=68 PD without pain n=74 Control n=54 P value
Age(years)a 66.85 ± 9.54 69.61±10.17 68.39±7.82 0.346
Gender (male %)b 39(57.4) 43(58.1) 30(55.6) 0.155
Disease duration (months)a 69.18±48.30 71.65±34.10   0.723
Age onset(years)a 61.07±9.61 63.64±10.12   0.125
UPDRS Ia 3.66±2.33 1.95±1.68   0.000
UPDRS IIa 12.57±6.10 9.04±4.94   0.000
UPDRS IIIa 25.13±12.60 20.27±10.95   0.015
UPDRS IVa 2.18±2.47 0.92±1.50   0.000
H/Y stagea 2.33±0.76 1.95±0.80   0.005
HRSDa 15.54±8.82 7.41±6.22   0.000
MoCAa 22.49±4.77 23.89±3.09   0.037
NMSQTa 8.38±4.87 4.61±3.16   0.000
Daily equivalent levodopa dosage(mg)a 313.92±189.50 375.35±250.10   0.104
Motor fluctuation (yes)c 33 17   0.001
Dyskinesias (yes)c 16 6   0.011
Table 1: Clinical features of patients and univariate statistical analysis, ameans and standard deviations; bpercentages; cnumber of patients say “yes”.